The biotech drug developer said Monday that it will pay $116.50 in cash for each share of Horizon, which makes a treatment for thyroid eye disease that generated more than $1 billion in its first full year on the market.
Shares of Horizon jumped 15% before the opening bell Monday.
U.S.-traded shares of the Irish company had already soared about 30% since it confirmed late last month that it had begun “highly preliminary discussions” about an acquisition with Amgen, the French drugmaker Sanofi, and Johnson & Johnson’s Janssen division.
Amgen had confirmed discussions were taking place and said that any offer it made for Horizon likely would be in cash.
The deal laid out Monday represents a premium of 48% to Horizon’s closing price of $78.76 before it made that late-November announcement.
The Horizon deal will give Amgen another chance to build its portfolio of rare-disease treatments after it closed in October a roughly $3.7 billion acquisition of ChemoCentryx, which focuses on autoimmune disease drugs.
Horizon Therapeutics, based in Dublin, develops potential treatments for rare, autoimmune and severe inflammatory diseases. Its best-seller, Tepezza, is only approved in the United States and treats eye bulging and double vision from thyroid eye disease.
U.S. regulators approved Tepezza in early 2020 as the first treatment for thyroid eye disease. The drug’s sales more than doubled last year to $1.67 billion. That’s about half of the company’s total sales of $3.23 billion.
The Food and Drug Administration gave Tepezza “orphan drug” status, which comes with financial incentives and exclusive marketing, benefits that are intended to encourage drugmakers to develop rare disease treatments.
Horizon also makes Krystexxa for uncontrolled gout. Sales of that treatment grew 39% last year to $565.5 million.
Shares of Amgen, based northwest of Los Angeles in Thousand Oaks, California, fell about 2% in premarket trading.
Source : CNBC